2015 Biotech Charity Contest Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2015 Biotech Charity Contest

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: alias_among_us	2/25/2015 9:57:02 PM
	Read Replies (1) of 407

My belated entry! (OT) 100% in Dilutis MEGA!Pharma:) (DILUQ) !!! A little background... Dilutis MEGA!Pharma:) (52-week range .002-.03) develops world-class eye treatments targeting Pre-blink Eye Aridity Syndrome (PEAS). Afflicting more than six billion people worldwide, PEAS causes less-than-optimal eye-moisture levels due to the synaptic transmission delay between a subconscious stimulus to blink and the involuntary reaction of blinking. This millisecond delay can cause extreme eye dryness and discomfort, whether or not that pain is perceived by the victim. Using best-in-class bioinformatics, CAR-T, and stem cell technologies, Dilutis MEGA!Pharma:) has developed its flagship product DI-231, an optimized hydro-saline-only solution designed to combat the ravages of PEAS. When quickly squirted into the eye at the precise moment – what Dilutis MEGA!Pharma:) defines as 'mid blink' – one is finally able to attain 100% eye-moisture maintenance when used regularly (up to 28,000x per day). In fact, a preclinical study achieved a 99-percent response rate in Chilean Sea Bass continuously submerged in the Company's hydro-saline solution. The success rate would have likely been 100% had not one pesky pescado flopped out of the holding tank and experienced complete body exhydration. A post hoc subgroup analysis revealed that subjects treated with DI-231 who were already taking Viagra/Cialis enjoyed potentially synergistic anti-underwater ED affects. I don't believe this potential has been fully factored into the stock price. I assign Dilutis MEGA!Pharma:) a $72.50/share value based on expected 2018 revenues and/or the average target of five random message board posters. (Obviously just kidding Bulba, love the contest)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next